Integra LifeSciences Holdings Corp. Director Stuart Essig Sells 114,431 Shares (IART)
Integra LifeSciences Holdings Corp. (NASDAQ:IART) Director Stuart Essig sold 114,431 shares of the company’s stock on the open market in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $49.58, for a total value of $5,673,488.98. Following the completion of the transaction, the director now directly owns 1,151,166 shares in the company, valued at approximately $57,074,810. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
IART has been the subject of a number of recent research reports. Analysts at Barclays raised their price target on shares of Integra LifeSciences Holdings Corp. from $45.00 to $50.00 in a research note to investors on Thursday. They now have an “equal weight” rating on the stock. Separately, analysts at Merrill Lynch upgraded shares of Integra LifeSciences Holdings Corp. to a “neutral” rating in a research note to investors on Wednesday. Finally, analysts at Bank of America Corp. upgraded shares of Integra LifeSciences Holdings Corp. from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday. Ten equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $46.88.
Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded down 0.04% during mid-day trading on Friday, hitting $49.48. The stock had a trading volume of 216,788 shares. Integra LifeSciences Holdings Corp. has a 52 week low of $30.87 and a 52 week high of $49.90. The stock has a 50-day moving average of $46.90 and a 200-day moving average of $42.13. The company’s market cap is $1.391 billion.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.02. The company had revenue of $213.20 million for the quarter, compared to the consensus estimate of $214.05 million. During the same quarter in the prior year, the company posted $0.85 earnings per share. The company’s quarterly revenue was up 1.5% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Corp. will post $2.53 EPS for the current fiscal year.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.